Ki-67蛋白表达在弥漫大B细胞淋巴瘤预后判断中的意义  

Prognostic Value of Ki-67 Protein Expressions in Patienties with Diffuse Large B-cell Lymphoma

作　　者：吴红卫[1] 黄蓉飞[1] 戴小珍[2] 

机构地区：[1]成都医学院附属医院,四川成都610500 [2]成都医学院,四川成都610500

出　　处：《四川医学》2014年第6期692-694,共3页Sichuan Medical Journal

摘　　要：目的探讨Ki-67蛋白表达在DLBCL中预后判断的意义。方法收集58例DLBCL患者的手术或活检标本并制作其组织芯片,采用免疫组化对DLBCL进行免疫表型分类,同时检测Ki-67蛋白的表达,并行CHOP方案化疗。结果58例DLBCL患者Ki-67表达高低与性别、年龄、LDH、结外病变、临床分期和IPI评分无关(P>0.05)。中位随访12个月后,生存曲线分析显示Ki-67高表达组中位疾病无进展生存时间(PFS)为16个月,短于Ki-67低表达组27个月,两组PFS差异有统计学意义(P<0.05)。结论在DLBCL患者中Ki-67高表达预后较差。Objective To explore the value of Ki-67 protein expressions in patients with diffuse large B-cell lymphoma （ DLBCL） for predicting prognosis. Methods To collect tissue samples from 58 patients with diffuse large B-cell lymphoma （ DL-BCL） , and making tissue chips, classifying them by the expressions of Ki-67 protein, and treating with CHOP chemotherapy. Results The highly or lowly expression of Ki-67 protein in 58 patients with diffuse large B-cell lymphoma （ DLBCL） is not related to gender、age、LDH、outside lymph node lesions、clinical stages and IPI score（P〉0. 05）.After a median follow-up of 12 months,the survival curves analysis shows that there are 16 months PFS for the groups with highly expression of Ki-67 protein, shorter than the groups with lowly expression of Ki-67 protein which are 27 months PFS,the differences of the PFS in these two groups are statistically significant（P〈0. 05）. Conclusion The highly expression of Ki-67 protein in patients with diffuse large B-cell lymphoma （ DLBCL） have the poor prognosis.

关 键 词：KI-67蛋白 DBLBCL 预后 

分 类 号：R733.1[医药卫生—肿瘤]